Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
120 participants
INTERVENTIONAL
2006-07-31
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CTEPH Identification an Standard Computerised Tomography Pulmonary Angiography in Pulmonary Embolism Patients
NCT03083093
Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli
NCT01935141
Ga68 V/Q PET/CT for Pulmonary Embolism Diagnosis: a Diagnostic Accuracy Study vs CT Pulmonary Angiography
NCT04179539
A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli
NCT00519506
V/Q SPECT for Diagnosis of Pulmonary Embolism
NCT01183026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Isovue
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With suspected PE
* Referred for MDCTA of pulmonary arteries
* Signed informed consent
Exclusion Criteria
* History of hypersensitivity to iodinated contrast agents
* Hyperthyroidism or pheochromocytoma
* Severe CHF
* Renal impairment
* Weight greater than 300 lbs
* Pacemaker
* Swan Ganz catheter
* Defibrillator or other intrathoracic metallic vascular device
* Received an investigational compound within 30 days of being in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bracco Diagnostics, Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steve Sireci, M.D.
Role: STUDY_DIRECTOR
Bracco Diagnostics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bracco Diagnostics, Inc.
Princeton, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IOP 106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.